Needham analyst Gil Blum lowered the firm’s price target on Mereo BioPharma (MREO) to $5 from $7 but keeps a Buy rating on the shares. The company announced that the Phase 3 Orbit study will continue towards a final analysis expected in Q4 after missing on its second interim, and this outcome represents the firm’s downside scenario, though Needham’s overall view on setrusumab’s ultimate likelihood of success remains unchanged, given that about 80% alpha spend is reserved for the final analysis, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MREO:
- Mereo BioPharma’s Phase 3 Study Progresses Smoothly
- Mereo Biopharma Group Plc: Buy Rating Maintained Amid Challenges and Promising Study Outcomes
- Promising Outlook for Mereo Biopharma’s Setrusumab Amid Phase 3 Trial Advances and Market Potential
- Closing Bell Movers: Ultragenyx slumps 25% on UX143 recommendation
- Ultragenyx, Mereo BioPharma receive DMC recommendation to continue Orbit study